3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
durvalumab
3
Fulvestrant
3
Cisplatin
3
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Carboplatin
2
ribociclib
1
repotrectinib
1
palbociclib
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
Radiation Dose Hypofractionation
1
RAD1901
1
Oviposition
1
Nivolumab
1
Mitomycin
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Drainage
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled